Table 3.
Compatibility of vanillic acid-, erythromycin- and tetracycline-responsive transgene control systems
| Inducer | −Tet /−Vac | −Tet /+Vac | +Tet/−Vac | +Tet/+Vac |
|---|---|---|---|---|
| CHO-VAC12 transfected with the tetracycline-responsive regulation system | ||||
| Relative SEAP production (%) | 100 ± 5.62 | 2.18 ± 0.31 | 101.04 ± 6.21 | 2.07 ± 0.29 |
| Relative SAMY production (%) | 100 ± 5.03 | 99.06 ± 4.53 | 4.53 ± 0.52 | 5.01 ± 1.61 |
| Inducer | −EM/−Vac | −EM/+Vac | + EM/−Vac | +EM/+Vac |
| CHO-VAC12 transfected with macrolide-responsive regulation system | ||||
| Relative SEAP production (%) | 100 ± 6.31 | 2.56 ± 0.09 | 102.19 ± 7.08 | 1.95 ± 0.59 |
| Relative SAMY production (%) | 100 ± 5.67 | 98.97 ± 7.73 | 5.20 ± 0.68 | 4.83 ± 1.22 |
CHO-VAC12 were co-transfected with pSAM200 (PSV40-tTA-pA) and pBP99 (PhCMV*-1-SAMY-pA) (A) or pWW35 (PSV40-ET1-pA) and pBP100 (PETR3-SAMY-pA) and grown for 48 h in the presence and absence of vanillic acid (Vac, 250 µM), erythromycin (EM, 2 µg/ml) or tetracycline (Tet, 2 µg/ml) before SEAP and SAMY production was assessed.